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1. Introduction  
Although extensive clinical data have established that the loss of Ikaros tumor suppressor 
activity via genetic inactivation is a major contributor to leukemogenesis leading to B-cell 
ALL, less is known about the role of Ikaros in T-cell leukemia. The T-cell malignancies 
observed in Ikaros-deficient mice suggest that Ikaros is likely to function as a tumor 
suppressor in T-cells.  In human, multiple studies have identified genetic inactivation of 
Ikaros (deletion or mutation) to be associated with ~5% of T-ALL cases. Additional studies 
provide evidence that the functional inactivation of Ikaros due to defects in signal pathways 
that normally regulate Ikaros activity is likely to be a critical factor in the development of T-
cell malignancies. These studies provide a rationale for new chemotherapeutic strategies  in 
the treatment of T-cell leukemia. In this chapter, we summarize the newest advances that 
shed light on the role of Ikaros in T-cell leukemia. 
2. Structure and function of Ikaros  
The Ikaros gene, discovered independently by K. Georgopoulos and S. Smale, encodes 
multiple Ikaros protein isoforms via alternate splicing (Lo et al. 1991; Georgopoulos et al. 
1992; Hahm et al. 1994). The structure of Ikaros protein reveals several known structural 
motifs corresponding to distinct functional domains as described below. 
2.1 Molecular structure of Ikaros  
2.1.1 DNA-binding domain 
The N-terminal region of the Ikaros protein contains four zinc finger motifs (Fig. 1). Three of 
these exhibit a typical C2H2 structure with two cysteines and two histidines covalently 
bound to a zinc atom, while the fourth zinc finger has a CCHC structure. The four N 
terminal zinc fingers in the Ikaros protein function in DNA binding. Point mutational 
analysis revealed that zinc fingers #2 and #3 are essential for the DNA-binding function of 
Ikaros, as well as its localization to pericentromeric heterochromatin (see 2.2.1). Based on 
DNA-se footprint analysis, it has been suggested that the first zinc finger contributes to 
DNA binding specificity. The role of the fourth zinc finger in DNA-binding remains 
unknown, although it has been noted that Ikaros isoforms that lack the fourth zinc finger 
exhibit a unique expression pattern during hematopoiesis (Payne et al. 2003). Recently, a 
point mutation in a single allele of the fourth zinc finger has been associated with primary 
immunodeficiency and pancytopenia in humans (Goldman, et al. In press.). 
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2.1.2 Dimerization domain 
The C-terminal region of the Ikaros protein contains two zinc finger motifs (Fig. 1). These 
zinc fingers do not bind DNA, but mediate protein-protein interactions with other Ikaros 
isoforms, and/or with Ikaros family proteins (Helios, Aiolos, etc.) that share the same motif 
(Sun et al. 1996). Every described Ikaros isoform contains the two C terminal zinc fingers, 
thus allowing for the formation of diverse Ikaros dimers with the potential for unique and 
specific functions. Ikaros binds DNA as a dimer, which underscores the importance of this 
domain for Ikaros function. 
2.1.3 Bipartite activation-repression domain 
All of the Ikaros proteins share a bipartite activation domain, that is adjacent to the two C-
terminal zinc fingers (Fig. 1). This domain is responsible for stimulating basal levels of 
transcription of Ikaros target genes (Sun et al. 1996; Georgopoulos et al. 1997). Within the 
bipartite activation domain, there are two distinct stretches of amino acids – acidic and 
hydrophobic. It has been established that acidic amino acids are responsible for transcriptional 
activation, while the hydrophobic amino acids do not exhibit such an effect (Sun et al. 1996). 
However, the presence of the hydrophobic amino acids next to the acidic stretch increases their 
transcriptional activation activity, suggesting that the hydrophobic residues have a functional 
role in transcriptional regulation (Sun et al. 1996; Georgopoulos et al. 1997).  
 
 
Fig. 1. Major structural features of the Ikaros protein. The Ikaros gene (Ikzf1) includes eight 
coding exons. Exon 1 is untranslated and was not identified in initial reports. Current 
Genbank sequences do not identify Exon 3B which encodes the 20 amino acid activation 
domain.   
2.1.4 Exon 3B activation domain 
Exon 3B of the Ikaros gene encodes a short, 20-amino acid stretch in the N region of the Ikaros 
protein (Fig. 1). This domain has been described (Hahm et al. 1994; Sun et al. 1999; Payne et al. 
2001) and functionally analyzed in human Ikaros (Ronni et al. 2007).  This domain has been 
shown to take part in determining the DNA-binding specificity of the Ikaros protein complex 
and in regulating the expression of Ikaros target genes (Ronni et al. 2007). 
We would like to emphasize that there are functionally significant domains of the Ikaros 
protein that are as yet unidentified. It is known that Ikaros can act as a transcriptional 
repressor and that it has a role in chromatin remodeling (see 2.2.2). However, the structures 
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and/or particular amino acids within the Ikaros protein that are responsible for these 
functions remain unknown. Further studies are needed to provide more detailed maps of 
the functional domains within the Ikaros protein.   
2.2 Ikaros function in regulating gene expression  
2.2.1 Ikaros regulates gene expression via chromatin remodeling 
Ikaros has been shown to regulate transcription by binding DNA at the upstream 
regulatory elements of its target genes (Georgopoulos et al. 1992; Ernst et al. 1993; Hahm 
et al. 1994; Molnar and Georgopoulos 1994). Thus, DNA binding is essential for Ikaros 
function. While Ikaros can directly activate or repress its target genes, subsequent 
experiments established that Ikaros function as a regulator of gene expression occurs via 
its role in chromatin remodeling. Studies by A. Fisher’s group demonstrated that Ikaros is 
abundantly localized in pericentromeric heterochromatin in cells (Brown et al. 1997). In 
pericentromeric regions, transcriptionally inactive genes have been shown to selectively 
associate with Ikaros foci, while transcriptionally active genes do not (Brown et al. 1997). 
The expression status of several genes that are differentially expressed during T and B cell 
maturation correlate with their association with Ikaros. Mutations in Ikaros binding sites 
interferes with the developmentally-regulated shut-down of the 5 gene (Sabbattini et al. 
2001), as well as the gene that encodes TdT (dntt) (Trinh et al. 2001) during lymphoid 
differentiation. These data further support a role for Ikaros in gene silencing via chromatin 
remodeling. Experiments by Georgopoulos’ group also demonstrated that Ikaros 
regulates expression of its target genes by recruiting them to pericentromeric 
heterochromatin, but that recruitment to pericentromeric heterochromatin can lead to 
activation of the target genes (Koipally et al. 2002). Studies in human T-cells revealed that 
Ikaros binding to human pericentromeric heterochromatin is regulated in a complex way 
by the association of different Ikaros isoforms. A model has been proposed whereby 
Ikaros regulates expression of its target genes by recruiting them to pericentromeric 
heterochromatin leading to either their activation or repression, and that switching from 
repression to activation depends on the presence of particular Ikaros isoforms in the 
Ikaros DNA-binding complex (Ronni et al. 2007; Kim et al. 2009). Thus, the current 
hypothesis is that Ikaros binds the upstream region of target genes and aids in their 
recruitment to pericentromeric heterochromatin, resulting in repression or activation of 
the target gene (Brown et al. 1997; Liberg et al. 2003). 
2.2.2 Molecular mechanisms of chromatin remodeling and gene regulation by Ikaros 
Ikaros associates with histone deacetylase (HDAC)-containing complexes (NuRD and 
Sin3A and Sin3B) (Koipally et al. 1999). Ikaros directly interacts with the NuRD complex 
ATPase, Mi-2, and with Sin3A and Sin3B through both its N-terminal and C-terminal 
regions (Kim et al. 1999; Koipally et al. 1999). The histone deacetylase complex acts as a 
transcriptional repressor via chromatin remodeling. It has been hypothesized that Ikaros 
recruits histone deacetylase complex to the upstream regulatory elements of its target 
genes resulting in chromatin remodeling and repression of the target genes (Brown et al. 
1997; Liberg et al. 2003).  
Ikaros has been shown to interact with the CtBP corepressor in vivo. This interaction with 
CtBP is achieved through amino acids at the N-terminal region of Ikaros (Koipally and 
Georgopoulos 2000). The Ikaros-CtBP complex acts as a transcriptional repressor. This 
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repression is HDAC-independent, and represents an additional means by which Ikaros 
represses transcription of its target genes (Koipally and Georgopoulos 2000).  
Ikaros also associates with Brg-1, a catalytic subunit of the SWI/SNF nucleosome 
remodeling complex that acts as an activator of gene expression (Kim et al. 1999; O'Neill et 
al. 2000). It has been hypothesized that Ikaros recruits the SWI/SNF nucleosome remodeling 
complex to the upstream regions of its target genes (in a similar fashion to the NuRD 
complex) resulting in chromatin remodeling and activation of its target genes. Thus, Ikaros 
can act as either an activator or a repressor of its target genes, depending on whether it 
associates with the NuRD, the CtBP or the SWI/SNF complex.  
3. Ikaros in T-cell development 
The role of Ikaros in normal T-cell development is demonstrated by evidence that Ikaros 
regulates the expression of key genes in T-cell differentiation and by the impaired T-cell 
differentiation observed in Ikaros-defficient mice.   
3.1 Ikaros regulates genes critical for the development of T-cells (TdT) 
The role of Ikaros in regulating expression of the gene encoding terminal deoxynucleotide 
transferase (TdT) during thymocyte differentiation has been extensively studied (Ernst et 
al. 1993; Ernst et al. 1996; Trinh et al. 2001; Su et al. 2005). Ikaros has been shown to bind 
in vivo to the D’ upstream regulatory element of the TdT  (dntt) gene. This region contains 
a perfect Ikaros consensus DNA-binding site, and mutational analysis has demonstrated 
that the presence of this sequence is essential for Ikaros binding to the upstream 
regulatory element of the TdT gene. This same region contains a consensus binding site 
that is bound in vivo by Elf-1, a member of the Ets family of transcription factors. The 
binding of Elf-1 and Ikaros have been shown to be mutually exclusive. Ikaros binding to 
the TdT upstream regulatory element leads to repositioning of the TdT gene to 
pericentromeric heterochromatin and to repression of TdT transcription. Elf-1, in contrast, 
acts as positive regulator of TdT expression. Thus, Ikaros and Elf-1 compete for occupancy 
of the same upstream control region during thymocyte development and have the 
opposite effect on TdT expression (Trinh et al. 2001). In CD4+CD8+ thymocytes, the 
upstream region of TdT is occupied by Elf-1 leading to expression of the TdT gene. During 
the induction of T-cell differentiation, Ikaros displaces Elf-1 from binding the upstream 
regulatory element of TdT, resulting in the loss of TdT expression. The absence of Ikaros 
results in failure to repress TdT expression during thymocyte differentiation leading to 
impaired T-cell development. The exact molecular mechanisms by which Ikaros displaces 
Elf-1 during thymocyte differentiation remains to be determined, although there is 
compelling evidence that the reversible phosphorylation of Ikaros (see 6.1 and 6.2 below) 
is responsible for this regulation.  
3.2 Ikaros regulation of CD4, CD8, and IL-2 expression  
During T-cell development, Ikaros has been demonstrated to bind to the regulatory element 
of the CD8 gene in vivo by chromatin immunoprecipitation (ChIP) assay. Ikaros has been 
hypothesized to positively regulate expression of the CD8gene during thymocyte 
differentiation (Harker et al. 2002). This has been supported by evidence that Ikaros-
defficient mice have decreased numbers of CD8+ T-cells (see 3.3 below).  
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Studies by Georgopoulos’ group demonstrated that Ikaros binds in vivo to a silencer that is 
located in the first intron of the Cd4 gene resulting in the suppression of Cd4 transcription. 
Further analysis revealed that Ikaros can bind concommitantly with the Mi-2 chromatin 
remodeler leading to suppression of the Cd4 silencer and upregulation of Cd4 gene 
expression. The Ikaros-Mi2 complex aids in recruitment of histone acetyl transferases. Thus 
Ikaros appeaars to be able to both activate or repress expression of Cd4 via chromatin 
remodeling (Naito et al. 2007).  
In mature CD4+ cells, Ikaros was shown to bind in vivo to the upstream regulatory element 
of the IL-2 gene. Further analysis demonstrated that Ikaros represses expression of the IL-2 
gene in mature CD4+ cells via chromatin remodeling. This established Ikaros as a regulator 
of anergy induction in CD4+ T-cells (Thomas et al. 2007).  
3.3 T-cell development in Ikaros-defficient mice  
Studies of Ikaros-deficient mice established Ikaros as a master regulator of T-cell 
development and identified several biological functions of Ikaros:  
1. Thymocytes that lack Ikaros expression progress from the double negative (DN) CD4–
CD8– to the double positive (DP) CD4+CD8+ stage in the absence of  selection (Wang 
et al. 1996). The proliferative response of thymocytes following TCR  ligation is ~9 fold 
higher in thymocytes from Ikaros null mice, compared to the wild-type. Thus, Ikaros 
has been identified as a key regulator of the  selection checkpoint in T-cell 
differentiation and a regulator of thymocyte expansion following  selection (Winandy 
et al. 1999).  
2. Thymocytes from Ikaros-deficient mice downregulate CD8 to become CD4 single 
positive (SP) thymocytes without positive selection signals that are normally required 
for differentiation from the DP to the SP stage (Winandy et al. 1999; Urban and 
Winandy 2004). Ikaros has also been shown to regulate negative selection that occurs 
during the DP stage (Urban and Winandy 2004). T-cell production in these mice is 
skewed toward the production of CD4 T-cells. Thus, Ikaros functions as a regulator that 
controls the TCR selection checkpoint in T-cell development, as well as a regulator of 
CD4 versus CD8 T-cell fate decisions (Wang et al. 1996; Winandy et al. 1999; Urban and 
Winandy 2004). 
3. Ikaros-deficient T-cells from all three Ikaros knock-out mice strains possess a lower 
activation threshold than normal T-cells and enter the cell cycle at an accelerated pace 
(Avitahl et al. 1999; Winandy et al. 1999). Thus, Ikaros sets the activation threshold in 
mature T-cells and regulates cell cycle progression.  
4. Ikaros and T-cell leukemia 
4.1 Ikaros-deficient mice develop T-cell leukemia 
The Ikaros-defficient mouse described above clearly established that Ikaros has an 
essential role in T-cell development. Subsequent analysis of heterozygous Ikaros-
defficient mice revealed that Ikaros has tumor suppressor activity. Between the second 
and third month of age, these mice display an aberration in thymic differentiation with an 
accumulation of triple-positive thymocytes that have intermediate expression levels of 
CD4, CD8, and the TCR complex (Winandy et al. 1995).  At the same time, a polyclonal 
expansion of mature T lymphocytes occurs in the spleen of these mice. Proliferation 
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assays established that thymocytes from heterozygous Ikaros-defficient mice have 
hyperproliferative potential, and that they can proliferate in the absence of TCR 
stimulation. It is worth noting that these changes precede the malignant transformation of 
thymocytes described below (Winandy et al. 1995). 
After 3 month of age, all of the Ikaros-defficient heterozygous mice develop T-cell leukemia 
and lymphoma (Winandy et al. 1995). This is manifested by severe generalized 
lymphadenopathy and splenomegaly, along with an increased number of malignant 
lymphoblasts in the peripheral blood. Flow cytometry analysis of malignant lymphoblasts 
established that they are monoclonal in origin, and that malignancy arises in the thymus. 
The expression analysis of maliganT-cells revealed that the wild type Ikaros copy was lost in 
these cells, thus they have a loss of Ikaros heterozygosity (Winandy et al. 1995). 
An additional Ikaros-defficient biological model provided evidence for the loss of Ikaros 
tumor suppressor activity in T-cell leukemia. This Ikaros-targeted mouse (IKL/L) had the -
galactosidase (gal) reporter gene inserted in-frame into exon 2 that is present in all known 
Ikaros isoforms. These mice produce very low levels of Ikaros proteins (Kirstetter et al. 2002; 
Dumortier et al. 2003; Dumortier et al. 2006). The IKL/L mice exhibit T lineage defects that 
are identical to those reported in Ikaros null mice including a lowered threshold to 
activation stimuli and the invariable development of thymic tumors. 
These findings strongly suggested that Ikaros acts as a tumor suppressor for T-cell leukemia. 
They also provide support for the hypothesis that Ikaros regulates normal thymocyte 
differentiation, and controls the proliferation of thymocytes and mature T-cells in response 
to TCR signaling. 
Further studies directly addressed the question of whether normal Ikaros function is 
essential and sufficient to induce tumor suppression of T-cell leukemia. The re-introduction 
of Ikaros via retroviral insertion into T leukemia cells that were derived from Ikaros-
defficient mice resulted in their cessation of growth (Kathrein et al. 2005). Expression of 
Ikaros in T-cell leukemia induced T-cell differentiation that was characterized by increased 
expression of CD4, CD69, CD5, and TCR. These data suggested that Ikaros tumor 
suppressor activity involves positive regulation of normal thymocyte differentiation, and 
that a potential mechanism for malignant transformation of Ikaros-defficient thymocytes 
involves failure of T-cell differentiation.  
The induction of T-cell differentiatiom following re-introduction of Ikaros was accompanied 
by induction of cell cycle arrest at the G0/G1 stage of the cell cycle (Kathrein et al. 2005). The 
exact mechanism by which Ikaros induces cell cycle arrest remains unknown, although it 
has been observed that the induction of Ikaros expression in leukemia cells correlates with 
the increased expression of the cell cycle-dependent kinase inhibitor p27kip1 (Kathrein et al. 
2005). One possibility is that Ikaros affects global chromatin remodeling, since restoration of 
Ikaros activity in T-cell leukemia correlates with a global increase in histone H3 acetylation 
(Kathrein et al. 2005). 
These complementary studies established Ikaros as a bona fide tumor suppressor in T-cell 
leukemia and demonstrate that the lack of Ikaros is the major causative factor of T-cell 
malignancy in Ikaros-deficient mice. 
4.2 Ikaros deficiency in human T-cell leukemia 
Since the discovery of the Ikaros gene and the identification of its function as a master 
regulator of lymphocyte differentiation and a tumor suppressor in mice, a number of studies 
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have examined human leukemia samples to determine if an alteration of Ikaros’ function is 
associated with the development of hematopoietic malignancies in humans. Increased 
expression of dominant-negative Ikaros isoforms has been associated with a variety of 
hematopoietic malignancies in humans. These include childhood ALL (Kuiper et al. 2007; 
Mullighan et al. 2007; Mullighan et al. 2008; Dovat and Payne 2010; Marcais et al.), adult B 
cell ALL (Nakase et al. 2000), myelodysplastic syndrome (Crescenzi et al. 2004), AML (Yagi 
et al. 2002), and adult and juvenile CML (Nakayama et al. 1999). Deletion of an Ikaros allele 
was detected in over 80% of BCR-ABL1 ALL and the deletion or mutation of Ikaros has been 
identified as a poor prognostic marker for childhood ALL (Mullighan et al. 2007; Mullighan 
et al. 2008; Martinelli et al. 2009; Martinelli et al. 2009; Martinelli et al. 2009; Mullighan et al. 
2009). These data established Ikaros as a major tumor suppressor in human leukemia. The 
most compelling data supporting the tumor suppressor activity of Ikaros in human 
hematopoietic malignancies was established for B-cell ALL.  
In T-cell ALL, the initial studies produced somewhat conflicting data. The first report 
described expression of dominant-negative Ikaros isoforms (using Western blot and RT-
PCR) in all 18 pediatric T-cell ALL patients that were studied (Sun et al. 1999), suggesting a 
strong correlation of the loss of Ikaros function with the development of T-cell ALL. 
However, subsequent studies on a total of 14 patients with T-cell ALL (both adult and 
pediatric) did not detect the presence of dominant-negative Ikaros isoforms (using Western 
blot and RT-PCR) in T-cell ALL (Nakase et al. 2000; Ruiz et al. 2004), although one study 
detected an association of the expression of a dominant-negative isoform of the Ikaros-
family member – Helios with T-cell ALL (Nakase et al. 2002). 
More comprehensive studies that utilized high-resolution CGH-arrays in a total of 81 
patients, detected deletion of one copy of Ikaros in 5% of T-cell ALL patients (Kuiper et al. 
2007; Maser et al. 2007; Mullighan et al. 2008). The most recent study of 25 cases of human T-
cell ALL, that combined Western blot, CGH-array analysis, and sequencing of Ikaros cDNA 
following RT-PCR, provided a more complete view of the relation of Ikaros and T-cell ALL. 
This study detected one patient (4%) in which one Ikaros allele had been deleted, while the 
Ikaros protein produced by the other intact allele exhibited a loss of nuclear localization 
with an abnormal localization in the cytoplasmic structure (Marcais et al. 2010). This study 
provided the first definitive functional evidence of the complete loss of Ikaros function and 
T-cell ALL in humans.   
In summary, studies in human T-cell ALL have demonstrated that genetic inactivation of 
the Ikaros gene by deletion or mutation does occur in human T-cell ALL in at least 5% of 
cases. Although Ikaros deletion is not as frequent an event in T-cell ALL when compared to 
B-cell ALL (30%) or BCR-ABL1 ALL (80%), it is a notable cause of T-cell ALL, and needs to 
be tested in newly diagnosed patients with this disease. The prognostic significance of 
Ikaros deletion in T-cell ALL remains to be determined. Studies also suggest that functional 
inactivation of Ikaros plays a significant role in T-cell ALL, although the mechanisms by 
which Ikaros function is impaired in T-cell ALL is still unknown. Recent findings discussed 
below provide insights into signal transduction pathways that potentially affect Ikaros 
tumor suppressor function in T-cell ALL.     
5. Mechanisms of Ikaros tumor suppressor activity 
The mechanisms of Ikaros tumor suppressor activity are not well understood. One major 
obstacle is the paucity of known Ikaros target genes. The best evidence for the mechanisms 
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of tumor suppression by Ikaros in T-cell ALL comes from studies that identified the role of 
Ikaros in the Notch pathway.  
5.1 Ikaros-mediated repression of the downstream effectors of the Notch pathway 
(Deltex and Hes1) 
The Notch pathway is essential for normal T-cell differentiation. However, activation of the 
Notch 1 gene has been found in over 50% of T-ALLs (Weng et al. 2004) and T-ALL leukemia 
cells often express the Notch target genes Hes-1 and pT (Chiaramonte et al. 2005). The 
intracelular domain of NotchIC forms a complex with the Notch transcription factor RBP-
Jk/CSL and the cofactor Mastermind. This complex activates expression of Notch pathway 
target genes. Studies by S. Chen’s group demonstrated that the Notch pathway is activated 
in the T-cell leukemia that develops in Ikaros-defficient mice (Dumortier et al. 2006). 
Additional analysis showed that Ikaros directly downregulates a Notch target gene, Hes-1. 
Ikaros directly competes with CSL for binding to the upstream regulator element of Hes-1 
(Kleinmann et al. 2008). Since CSL acts as a stimulator of transcription, and Ikaros represses 
transcription of Hes-1, Ikaros counteracts the pro-oncogenic Notch signaling in T-cell ALL. 
Repression of Hes-1 by Ikaros likely involves chromatin remodeling since Ikaros binding to 
the upstream regulatory region of Hes-1 leads to a decrease in histone H3 acetylation 
(Kathrein et al. 2008), and Ikaros-defficient mice have reduced trimethylation of histone H3 
at the K27 residue (Kleinmann et al. 2008).  
A link between Ikaros deficiency and Notch activation in T-cell ALL had been suggested by 
Beverly and Capobianco (Beverly and Capobianco 2003). They found synergism between 
Notch activation and the inactivation of Ikaros in T-cell leukemogenesis. Sequence analysis 
of the consensus binding sequence for CSL and Ikaros revealed remarkable similarities and 
the authors hypothesized that Ikaros may interfere with CSL binding and Notch signaling 
(Beverly and Capobianco 2003).    
Additional experiments showed that Ikaros represses another target gene of the Notch 
signaling pathway – Deltex1 (Kathrein et al. 2008). Similarly to the regulation of Hes-1, 
Ikaros competes with CSL for binding to the upstream regulatory region of Deltex1 and 
represses expression of Deltex1 by chromatin remodeling. Ikaros binding to the upstream 
region of Deltex1 also results in decreased histone H3 acetylation (Kathrein et al. 2008). 
These data strongly suggest that one of the mechanisms by which Ikaros suppresses 
leukemogenesis in T-cells involves inhibition of the Notch signal transduction pathway. 
5.2 Additional mechanisms of Ikaros tumor suppressor activity in T-cell ALL   
One possible explanation for why the lack of Ikaros function leads to leukemia is the fact 
that Ikaros regulates expression of several genes that are essential for normal T-cell 
development (section 3 above). Often, malignant transformation is characterized by a 
failure (or arrest) of normal differentiation. Thus, the absence of Ikaros activity and its 
subsequent impact on T-cell differentiation is likely to be an important step toward the 
development of leukemia.  
It has been demonstrated that Ikaros can negatively regulate cell cycle progression at the 
G1/S transition (Gomez-del Arco et al. 2004), thus the absence of Ikaros would impair the 
G1/S check point in the regulation of the cell cycle. 
Several reports suggested that Ikaros downregulates Bcl-xL expression (Yagi et al. 2002; 
Ezzat et al. 2006; Kano et al. 2008). Thus, Ikaros might regulate apoptosis, and the lack of 
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Ikaros activity would have an oncogenic effect similar to the overexpression of Bcl2 in 
chronic lymphocytic leukemia (CLL). This would also lead to the development of leukemia 
that is more highly resistance to chemotherapy. 
In summary, multiple mechanisms including the loss of Notch pathway inhibition, blocked 
T-cell differentiation and impaired cell cycle control are likely to play a role in the T-cell 
leukemogenesis that occurs with the loss of Ikaros activity. However, the specific 
mechanisms by which Ikaros exerts its tumor suppressor activity remain largely unknown. 
Identification of additional genes that are regulated by Ikaros will provide more insight on 
this important process. 
6. Regulation of Ikaros’ function in T-cell leukemia 
6.1 Phosphorylation of Ikaros by CK2 kinase inactivates the Ikaros protein 
Despite the fact that Ikaros plays a critical role in regulating T-cell proliferation and 
differentiation, the level of Ikaros expression remains high throughout the cell cycle and 
during lymphocyte differentiation. This suggests that Ikaros function is regulated by 
posttranslational modifications. The role of phosphorylation in regulating Ikaros function 
has been studied the most extensively. Studies that identified mitosis-specific 
hyperphopshorylation of Ikaros at an evolutionarily conserved linker sequence, provided 
evidence that the cell cycle-specific phosphorylation of Ikaros regulates its DNA-binding 
ability and nuclear localization during mitosis (Dovat et al. 2002). This provided the first 
evidence that phosphorylation can regulate Ikaros function in cells.  
Subsequent studies demonstrated that Ikaros is a direct substrate of Casein Kinase II (CK2) 
and that CK2-mediated phosphorylation regulates multiple functions of Ikaros in normal 
and leukemia cells: 
Experiments performed by Georgopoulos’ group identified several amino acids located in 
the C-terminal region of the Ikaros protein that are directly phoshorylated by CK2. 
Mutational analysis of phosphoacceptor sites revealed that CK2-mediated phosphorylation 
regulates Ikaros’ ability to control cell cycle progression during the G1/S transition.  
Studies by Dovat’s group identified additional phosphorylation sites in the N-terminal 
region of the Ikaros protein that are phosphorylated by CK2 (Gurel et al. 2008). Experiments 
with Ikaros phosphomimetic mutants (that mimic constitutive phosphorylation) and 
phosphoresistant mutants (that mimic constitutive dephosphorylation) revealed that CK2-
mediated phosphorylation of two amino acids located in the N-terminal region of Ikaros 
controls two essential functions of Ikaros: 1) Ikaros’ DNA-binding activity and 2) Ikaros’ 
subcellular localization to pericentromeric heterochromatin (Gurel et al. 2008). Increased 
phosphorylation of Ikaros by CK2 results in severely decreased DNA-binding affinity and 
the loss of pericentromeric localization, thus CK2-mediated phosphorylation leads to 
inactivation of Ikaros function (Gurel et al. 2008).   
6.2 CK2-mediated phosphorylation controls Ikaros function in T-cell differentiation  
The significance of CK2-mediated phosphorylation for normal T-cell development was 
underscored by the discovery that Ikaraos in CD4+CD8+ thymocytes is phosphorylated at 
multiple sites by CK2 (Gurel et al. 2008). As described above, in thymocytes, Ikaros binds to 
the upstream regulatory region of its target gene, TdT, leading to repression of TdT 
transcription. Phosphorylation of Ikaros in CD4+CD8+ thymocytes by CK2 decreases its 
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DNA-binding affinity toward the upstream regulatory element of TdT, which results in 
occupancy of this region by the transcription factor Elf-1 and expression of TdT. During 
induction of thymocyte differentiation, Ikaros undergoes dephosphorylation at amino acids 
#13 and #294 (Gurel et al. 2008). Differentiation-specific dephosphorylation of Ikaros results 
in its increased DNA-binding affinity toward the upstream regulatory element of TdT, 
displacement of Elf-1, and repression of TdT transcription. These data demonstrate that the 
regulation of Ikaros phosphorylation by CK2 plays an important role in T-cell differentiation 
and suggest that increased activity of CK2 kinase in thymocytes would lead to impaired T-
cell development due to interference with normal Ikaros function.  
6.3 CK2-mediated phosphorylation leads to ubiquitination and degradation of the 
Ikaros protein 
Further functional analysis of Ikaros phosphorylation revealed that CK2-mediated 
phosphorylation occurs at PEST sequences in the Ikaros protein. PEST sequences are 
comprised of a region that is rich in Proline (P), Gluamate (E), Serine (S) and Threonine (T).   
It has been demonstrated that phosophorylation of the serines or threonines located within 
the PEST sequence typically results in increased degradation of the respective protein. 
Ikaros contains two PEST sequences that are phosphorylated in vivo by CK2 (Popescu et al. 
2009). Phosphorylation at PEST sequences leads to decreased half-life and increased 
degradation of Ikaros, resulting in a low level of Ikaros protein in cells. Hyperphoshorylated 
Ikaros undergoes polyubiquitination, which leads to its degradation via the ubiquitin/ 
proteasome pathway (Popescu et al. 2009).  
6.4 Dephosphorylation of Ikaros by PP1 opposes CK2-mediated phosphorylation 
The discovery that Ikaros is a direct substrate for Protein Phosphatase 1 (PP1) (Popescu et al. 
2009), a well-known tumor suppressor protein, provided additional evidence that 
phosphorylation plays an extremely important role in the regulation of Ikaros activity in 
normal hematopoiesis and in leukemia. Ikaros interacts with PP1 directly by binding via  a 
PP1 consensus recognition motif that is located near the C-terminal zinc fingers. 
Dephosphorylation of Ikaros by PP1 is essential for preservation of Ikaros DNA-binding 
activity and subcelular localization to pericentromeric heterochromatin (Popescu et al. 2009). 
Mutated Ikaros protein that is unable to interact with PP1 undergoes accelerated 
degradation via the ubiquitin pathway. This results in a 5- to 10-fold decrease in the level of 
Ikaros protein in cells, when compared to wild type Ikaros (Popescu et al. 2009). Thus, PP1-
mediated dephosphorylation of Ikaros counteracts the effect of CK2-mediated 
phosphorylation of Ikaros. This provides evidence that two major signal transduction 
pathways – one involving CK2 and the other PP1 – converge on the Ikaros protein (Fig. 2). 
These pathways exert opposite effects on Ikaros function and thus regulate T-cell 
differentiation and proliferation.  
Both CK2 and PP1 proteins are known to play a critical role in malignant transformation. 
Increased expression of CK2 during T-cell differentiation results in the development of T-
cell leukemia in mice (Seldin and Leder 1995). Furthermore, CK2 activity is elevated in 
many other types of human malignancies (Phan-Dinh-Tuy et al. 1985; Pinna 1997; Roig et al. 
1999; Kim et al. 2007). The activity of CK2 and PP1 is closely tied to the ability of cells to 
proliferate, and thus the balance of their function is essential to prevent malignant 
transformation. Both CK2 and PP1 exerts strong effects on multiple functions of Ikaros – its 
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role in T-cell differentiation, ability to regulate cell cycle progression, DNA-binding affinity, 
chromatin remodeling capability (by controlling its subcellular localization to 
pericentromeric heterochromatin), regulation of gene expression, and protein stability. This 
suggests that the pro-oncogenic activity of CK2 involves inactivation of the Ikaros gene, 
while the tumor suppressor activity of PP1 is mediated by preserving the tumor suppressor 
function of Ikaros. These data also strongly suggest that in leukemia cells that have 
increased activity of CK2, but no deletion/mutation in the Ikaros gene, the Ikaros protein 
that is present is unlikely to be a functionally active Ikaros protein with tumor suppressor 
activity. Instead, recent discoveries suggest that the functional inactivation of Ikaros by 
CK2-mediated hyperphopshorylation might be one important mechanism leading to T-cell 
leukemia. This provides new insight into the role of Ikaros, CK2, and PP1 in T-cell leukemia, 
and identifies CK2 kinase as a potential target for novel chemotherapy for T-cell ALL.  
 
 
 
 
 
 
Fig. 2. CK2 kinase-mediated hyperphosphorylation results in functional inactivation of 
Ikaros and T-cell ALL.  Hyperphosphorylation of Ikaros by CK2 kinase leads to the loss of 
Ikaros’ ability to bind DNA, control cell cycle progression, regulate chromatin remodelling, 
regulate gene expression and to increased degradation of the Ikaros protein. The loss of 
Ikaros tumor suppressor function leads to the development of T-cell ALL. 
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7. Conclusion: The role of Ikaros in T-cell leukemia – overall hypothesis 
Numerous clinical and experimental studies established the absence of Ikaros activity as a 
causative and/or contributory factor to the development of T-cell ALL. While genetic 
inactivation of Ikaros is evident in about 5% of T-cell ALL, recent evidence suggests that the 
functional inactivation of Ikaros by CK2 kinase-mediated phosphorylation is an important 
factor for the development of T-cell ALL. With regard to Ikaros activity, we propose that 
there are three types of T-cell leukemia (Fig. 3):   
4. T-cell leukemia with the presence of genetic inactivation (deletion or mutation) of at 
least one Ikaros allele – responsible for ~5% of T-cell leukemia. 
5. T-cell leukemia with functional inactivation of the Ikaros protein in leukemia cells due 
to overexpression of CK2 kinase. 
6. T-cell leukemia with intact Ikaros function, but with defects in other genes and proteins 
that regulate T-cell proliferation and differentiation.  
The prognostic and therapeutic significance of these three types of T-cell leukemia will be 
the  subject of intense investigation in the future. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Three types of T-cell leukemia with regards to Ikaros activity. Genetic and functional 
inactivation of Ikaros, in addition to changes in previously identified pathways, lead to T-
cell leukemogenesis. 
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